Table 1 FDA-approved immune checkpoint inhibitors in cancer immune oncology
Inhibitor | Target | Ligand/receptor | Year of approval | Cancer types |
|---|---|---|---|---|
Atezolizumab (Tecentriq) | PD-L1 | PD-1 | May-2016 | Bladder cancer/ NSCLC |
Avelumab (Bavencio) | PD-L1 | PD-1 | November-2015 | Bladder cancer/ Merkel cell carcinoma |
Durvalumab (Imfinzi) | PD-L1 | PD-1 | February-2016 | Bladder cancer |
Nivolumab (Opdivo) | PD-1 | PD-L1, PD-L2 | March-2015 | Bladder cancer/ Head and neck cancer (squamous cell carcinoma)/ Classical Hodgkin lymphoma/ Melanoma/ Mismatch repair deficient and microsatellite instability-high colorectal cancer/ NSCLC / Renal cell (kidney) cancer |
Pembrolizumab (Keytruda) | PD-1 | PD-L1, PD-L2 | September2014 | Bladder cancer/ Head and neck cancer (squamous cell carcinoma)/ Classical Hodgkin lymphoma/ Melanoma/ Mismatch repair deficient and microsatellite instability-high solid tumors / NSCLC |
Cemiplimab (Libtayol) | PD-1 | PD-L1, PD-L2 | September-2018 | NSCLC/ Squamous Cell Carcinoma of skin/ Basal Cell Carcinoma |
Ipilimumab (Yervoy) | CTLA-4 | Cd80/CD86 | March-2011 | Melanoma |